Kevin Kunzmann

Pitha discusses how ophthalmic drug shortages — more frequent and longer-lasting than the national average — are threatening adherence to glaucoma therapy.

US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.

Advertisement The US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.

By Sophia Tam As medication experts and some of the most accessible health-care providers, pharmacists play an important role in helping

Key Takeaways An open-label phase 3 design randomized nonprogressing, immunotherapy-naïve metastatic NSCLC after 12-week nivolumab/ipilimumab induction to continued therapy with or without LCT. Median OS numerically favored nivolumab/ipilimumab alone (52.8 vs 43.2 months; HR 1.14; P=.54), prompting early closure for futility. Progression-free survival was not improved by LCT (24.3 vs 32.2 months; HR 0.79; P=.220), despite the intent to eradicate residual/resistant clones. Oligometastatic outcomes did not benefit from LCT, with OS and PFS trends favoring omission of local therapy (OS HR 1.68; P=.121; PFS HR 1.38; P=.284). Safety remained broadly similar, but pneumonitis occurred in 9.5% with LCT and absolute lymphocyte counts were lower upon systemic therapy re-initiation. SHOW MORE

Key Takeaways NAUTIKA1 enrolled stage IB–III (selected IIIB T3N2) and permitted adjuvant chemotherapy, followed by 2 years of alectinib. ALNEO focused on stage III only and prohibited chemotherapy, yet showed similarly strong pathologic regression and nodal downstaging with perioperative alectinib. LORIN evaluated lorlatinib in borderline resectable/unresectable stage III, including substantial N3 disease, achieving high pCR/MPR rates and marked nodal downstaging. Comprehensive NGS is increasingly required in early-stage NSCLC to identify actionable alterations before initiating chemoimmunotherapy and to enable optimal perioperative sequencing. Emerging phase 3 strategies include adjuvant selpercatinib for RET fusions, Beamion LUNG-3 with adjuvant zongertinib for HER2 TKD mutations, and zipalertinib for EGFR exon 20 insertions. SHOW MORE

Key Takeaways RC148 plus chemotherapy achieved a 90.0% ORR in squamous (n=27) and 75.9% ORR in nonsquamous NSCLC (n=22) at 10 mg/kg. Hematologic adverse events predominated, while immune-related and VEGF-related toxicities were generally low grade, and grade ≥3 hemorrhage was not observed at 10 mg/kg. Engineering features include an established anti–PD-1 backbone, a nanobody anti-VEGF moiety for potential penetration/stability advantages, and Fc silencing to reduce ADCC/ADCP-mediated toxicity. Phase 3 evaluation is progressing in first-line squamous NSCLC, and FDA-endorsed initiation of a global AbbVie-sponsored phase 3 program aims to confirm translatability beyond a Chinese population. SHOW MORE

The pioneer in neuroimmune research and itch physiology discusses how treatment innovation has evolved dermatology—and what still needs to be changed in pr